About the Company
bio-path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary dnabilize™ technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. the company’s initial focus is in oncology. bio-path’s lead product candidate, prexigebersen, (bp1001), is in phase ii clinical trials for aml in combination with ldac in elderly de novo patients. the safety segment of the phase ii trial for prexigebersen + dasatinib in blast-phase and accelerated phase cml patients is expected to begin in 2017. bio-path’s second drug candidate, bp1002, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. the technology behind prexigebersen is called dnabilize™ technology. dnabilize is a liposomal antisense dna platform with two critical improvements in oligonucleotide therapeutics. the main benefits to the patient are, 1: we have never had a single patient experience thrombocytopen
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BPTH News
BPTH Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on ...
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript
Path Holdings, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the ...
Why Bio-Path Holdings Shares Are Falling Today
Bio-Path reported a net loss of $33.63 per share for the year ended Dec. 31, 2023, lower than $38.12 per share in the ...
Bio-Path Holdings Reports Full Year 2023 Financial Results
HOUSTON, March 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to ...
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
HOUSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH) (the “Company”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle ...
Bio-Path Holdings Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
(RTTNews) - Biotechnology company, Bio-Path Holdings, Inc. (BPTH), Wednesday announced a reverse stock split at $0.001 per share in the ratio 1-for-14, which will be effective from 5:30 p.m ...
Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Full Year 2023 Financial Results
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop ...
Bio-Path Holdings, Inc.: Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
HOUSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH) (the "Company"), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle ...
Bio-Path Holdings Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...